Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics

被引：0

作者：

Andreas A. Argyriou

Jordi Bruna

Armando A. Genazzani

Guido Cavaletti

机构：

[1] Saint Andrew's State General Hospital of Patras,Department of Neurology

[2] Unit of Neuro-Oncology,Department of Cell Biology

[3] Hospital Universitari de Bellvitge-ICO l'Hospitalet,Department of Pharmaceutical Sciences

[4] Bellvitge Institute for Biomedical Research (IDIBELL),undefined

[5] Hospital Duran i Reynals,undefined

[6] Physiology and Immunology,undefined

[7] Universitat Autònoma de Barcelona,undefined

[8] Centro de Investigación Biomédica en Red (CIBERNED),undefined

[9] Università del Piemonte Orientale,undefined

[10] Experimental Neurology Unit,undefined

[11] School of Medicine and Surgery and Milan Centre for Neuroscience,undefined

[12] School of Medicine — University of Milano-Bicocca,undefined

来源：

Nature Reviews Neurology | 2017年 / 13卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Peripheral neurotoxicity is potentially permanent and ranks among the most common non-haematological adverse effects of chemotherapyIdentifying patients at high risk of chemotherapy-induced peripheral neurotoxicity (CIPN) is paramountThe identification of a clinical or genetic profile that can detect patients at high risk of CIPN still represents an unmet needThe methodology of pharmacogenetic studies on CIPN could be improvedFurther studies are warranted to identify genetic associations that could inform the management of patients with CIPN

引用

页码：492 / 504

页数：12

共 105 条

[81]

Wheeler HE(undefined)An inherited genetic variant in undefined undefined undefined-undefined

[82]

Hertz DL(undefined) promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia undefined undefined undefined-undefined

[83]

Eckhoff L(undefined)Lack of association of the undefined undefined undefined-undefined

[84]

Park SB(undefined) rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population undefined undefined undefined-undefined

[85]

Lee SY(undefined)Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma undefined undefined undefined-undefined

[86]

Jordan MA(undefined)Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide undefined undefined undefined-undefined

[87]

Wilson L(undefined)Pharmacogenomics in the clinic undefined undefined undefined-undefined

[88]

Lobert S(undefined)Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update undefined undefined undefined-undefined

[89]

Vulevic B(undefined)Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing undefined undefined undefined-undefined

[90]

Correia JJ(undefined)undefined undefined undefined undefined-undefined

← 2 3 4 5 6 7 8 9 10 11 →